Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or
without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) ,
determining whether concurrent chemoradiotherapy(CCRT) combined with nimotuzumab can improve
the survival rate of high-risk patients and may provide new evidence for individualized
comprehensive treatment of locally advanced NPC.